A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Difenoxin
Bleselumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bleselumab.
Difenoxin
Nemolizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Nemolizumab.
Difenoxin
Mitazalimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Mitazalimab.
Difenoxin
Suvratoxumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Suvratoxumab.
Difenoxin
Asunercept
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Asunercept.
Difenoxin
Ponezumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ponezumab.
Difenoxin
Zolbetuximab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Zolbetuximab.
Difenoxin
Utomilumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Utomilumab.
Difenoxin
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Telisotuzumab vedotin.
Difenoxin
Tigatuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tigatuzumab.
Difenoxin
Tezepelumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tezepelumab.
Difenoxin
Frovocimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Frovocimab.
Difenoxin
Abrilumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Abrilumab.
Difenoxin
Ipafricept
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ipafricept.
Difenoxin
Tafasitamab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tafasitamab.
Difenoxin
Apomab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Apomab.
Difenoxin
Gremubamab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Gremubamab.
Difenoxin
Pateclizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Pateclizumab.
Difenoxin
Dalantercept
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Dalantercept.
Difenoxin
Margetuximab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Margetuximab.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3